Stock Analysis

IQVIA Holdings (IQV) Updates 2025 Revenue Guidance and Completes Share Buyback

NYSE:IQV
Source: Shutterstock

IQVIA Holdings (IQV) recently updated its earnings guidance for 2025 with expectations of revenue ranging between $16,100 million and $16,300 million. This update coincides with the company's Q2 earnings announcement, showing an increase in sales to $4,017 million but a decline in net income to $266 million. During the last quarter, IQVIA's share price rose 11%, likely supported by its ongoing share buyback program, where the company repurchased 3,985,000 shares. Despite the broader market fluctuations amid record highs reached by the S&P 500 and Nasdaq, IQVIA's proactive measures appear aligned with its recent share price uptick.

We've discovered 1 weakness for IQVIA Holdings that you should be aware of before investing here.

IQV Revenue & Expenses Breakdown as at Jul 2025
IQV Revenue & Expenses Breakdown as at Jul 2025

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

The recent update in IQVIA Holdings' earnings guidance and its ongoing share buyback program suggest a focused strategy to enhance shareholder value, aligning with the uptick in its share price. However, the total return including share price and dividends over the past five years shows a 2.05% decline, indicating challenges in achieving sustainable long-term growth. This performance contrasts with the broader market's one-year performance, where IQVIA underperformed the US Life Sciences industry, which itself experienced a 22% decline.

The company's anticipated revenue range of US$16.1 billion to US$16.3 billion by 2025 and partnerships like those with NVIDIA could provide a cost advantage and potentially elevate margins, important factors amid macroeconomic pressures. Analysts foreseeing revenue growth of 5.2% annually over the next three years could see risks should sector funding conditions deteriorate. The current share price is below the consensus price target of US$190.67, suggesting potential for appreciation if earnings and revenue forecasts materialize as expected, though differing analyst views present varying degrees of confidence in this forecast.

Understand IQVIA Holdings' track record by examining our performance history report.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NYSE:IQV

IQVIA Holdings

Provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.

Undervalued with limited growth.

Advertisement